American pharma giant Pfizer has enlisted the help of technology multinational IBM in an ambitious bid to transform both care and treatment for Parkinson's disease.
As the US FDA moves towards issuing final guidelines on biosimilars, recent research with specialists in five main therapy areas suggests they are willing to embrace them if efficacy and safety
